PAT at Rs 7.5 bn grew 113% y-o-y (+12.4% q-o-q). Revenues of Rs 51.7 bn (+18.3% y-o-y; +2.6% q-o-q) were primarily driven by strong traction in India formulations, and gProventil …
Tag:
Cipla
-
-
Market participants will keep tabs on corporate earnings, COVID-19 vaccine rollout, foreign fund inflow, macroeconomic data and other global cues. Nifty futures were trading 19.50 points or 0.13 per cent …
